Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE long-term open-label safety study of seladelpar in primary biliary cholangitis
2024-511753-22-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Gilead Sciences. Primary endpoint: Treatment-emergent adverse events, biochemistry, and hematology. Planned start May 2021; status: authorised.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-511753-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511753-22-00.